Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery

Ann Thorac Surg. 2017 Jan;103(1):e9-e10. doi: 10.1016/j.athoracsur.2016.06.068.

Abstract

Management of heparin-induced thrombocytopenia (HIT) entails cessation of heparin and initiation of a nonheparin parenteral anticoagulant such as danaparoid. Danaparoid cross-reactivity with HIT antibodies is an uncommon complication of treatment of HIT. We report the case of confirmed HIT and in vivo cross-reactivity with danaparoid, complicating severe sepsis due to an infectious endocarditis treated by cardiac surgery.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / immunology
  • Anticoagulants / therapeutic use
  • Cardiac Surgical Procedures*
  • Chondroitin Sulfates / immunology*
  • Chondroitin Sulfates / therapeutic use
  • Cross Reactions
  • Dermatan Sulfate / immunology*
  • Dermatan Sulfate / therapeutic use
  • Heart Valve Diseases / surgery*
  • Heparin / adverse effects
  • Heparin / immunology*
  • Heparitin Sulfate / immunology*
  • Heparitin Sulfate / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Thrombocytopenia / complications*
  • Thrombocytopenia / immunology

Substances

  • Anticoagulants
  • Dermatan Sulfate
  • Heparin
  • Chondroitin Sulfates
  • Heparitin Sulfate
  • danaparoid